Catalyst
Slingshot members are tracking this event:
Phase 3 data of Firdapse in Congenital Myasthenic Syndromes (CMS) due 1H 2019
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CPRX | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 30, 2019
Occurred Source:
https://www.globenewswire.com/news-release/2019/10/30/1937692/0/en/Catalyst-Pharmaceuticals-Announces-Top-Line-Results-of-CMS-001-a-Phase-3-Trial-of-Firdapse-Amifampridine-Phosphate-in-Patients-with-Congenital-Myasthenic-Syndromes-CMS.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Firdapse, Congenital Myasthenic Syndrome, Cms
